The expansion of drug procurement with quantity was officially launched. One variety can be won by many companies.


Release time:

2019-09-04

 

On the morning of September 1, Shanghai sunshine pharmaceutical procurement network officially announced the "centralized drug procurement document in the alliance area", and the pilot cities for centralized drug procurement and use organized by the state (hereinafter referred to as "47" cities) were officially expanded. According to the document, the expansion of the collection will be launched in Shanxi, Inner Mongolia, Liaoning and other 25 regions, involving the first batch of pilot atorvastatin oral regular release dosage forms and other 25 winning products, but also the introduction of "multiple winning" new regulations. The expansion of national belt procurement was officially launched.

According to the document, on the basis of the results of the implementation of centralized procurement in "4 7" cities and provinces that have been followed up, the state has organized relevant regions to form alliances to carry out centralized procurement of drugs in cross-regional alliances in accordance with the law. The alliance areas include Shanxi, Inner Mongolia, Liaoning, Jilin, Heilongjiang, Jiangsu, Zhejiang, Anhui, Jiangxi, Shandong, Henan, Hubei, Hunan, Guangdong, Guangxi, Hainan, Sichuan, Guizhou, Yunnan, Tibet, Shaanxi, Gansu, Qinghai, Ningxia, Xinjiang (including Xinjiang production and Construction Corps), except for "47" cities in the alliance area.

The purchased varieties are atorvastatin, rosuvastatin, clopidogrel, irbesartan and other 25 varieties, which are covered by public medical institutions in the alliance area, some military and social medical institutions. The calculation base of the agreed procurement volume in the first year of this centralized procurement of drugs shall be determined by each alliance region. The actual winning enterprise for the agreed purchase quantity in the first year is 1, and the agreed purchase quantity is 50% of the calculation base for the agreed purchase quantity in the first year; There are 2 enterprises in the actual selection, and the agreed purchase quantity is 60% of the calculation base for the agreed purchase quantity in the first year. In fact, there are 3 enterprises in the selection, and the agreed purchase quantity is 70% of the calculation base for the agreed purchase quantity in the first year. In principle, the agreed purchase volume of the following year shall not be less than the agreed purchase volume of the first year of the selected variety.

The document announced the first year of the provinces agreed procurement volume, the Shanghai Stock Exchange reporter according to the first year of the quantitative base estimates, Zhejiang, Jiangsu's quantitative base accounted for more than 10% of the total of 25 regions, Henan, Shandong share close, ranked high.

In addition, according to the requirements of the document, the procurement cycle is determined according to the following rules: if the selected enterprise does not exceed 2 (inclusive) varieties, the current procurement cycle is in principle 1 year; The selected enterprise is 3 varieties, and the current procurement cycle is 2 years in principle. The procurement cycle may be extended by one year, depending on the actual situation. Each region shall appoint representatives to participate in the joint procurement office, and the Shanghai Pharmaceutical Centralized Bidding and Procurement Affairs Management Office shall undertake the daily work and implement it. On the morning of September 24, the enterprise will declare, and the confirmation of the supply area will begin in the afternoon of the same day.

According to the document, the procurement volume of this alliance collection increased compared with the previous "4 plus 7" belt procurement, of which some varieties increased significantly. According to the calculation of the maximum possible purchase volume, I .e. 70% of the purchase volume, the largest change is enalapril of 5mg specification. The purchase volume is about 14 times of the previous "4+7" belt purchase volume, from 8.2152 million tablets to 113.4598 million tablets. The purchase volume also has a larger increase of the targeted drug gefitinib, which is about 11.7 times of the previous purchase volume.

 

Industry insiders said that although the expansion of the belt procurement city only focused on 25 selected varieties, the actual radiation range will have a greater impact. For the previous "4 7" volume procurement of the non-selected enterprises in the relevant drug varieties, has appeared in the past six months in many provinces to actively apply for price reduction. In addition, the market competitiveness of varieties that have not passed the consistency evaluation is further attenuated. For the current pharmaceutical companies, price cuts are irreversible, and a more practical approach is to win the market by exchanging price for quantity.